Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Vicaut

Showing results (471-480 of 522) with videos related to

Pageof 53
Sort By:
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
The New England Journal of Medicine|November 6, 2012
Bedside monitoring to adjust antiplatelet therapy for coronary stentingJean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, et al.
Circulation. Cardiovascular Interventions|July 18, 2020
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot StudyGuillaume Duthoit, Johanne Silvain, Eloi Marijon, et al.
Circulation|September 2, 2024
Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical TrialMarie Hauguel-Moreau, Paul Guedeney, Claire Dauphin, et al.
American Journal of Respiratory and Critical Care Medicine|May 19, 2025
Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled TrialMatthieu Legrand, Edouard Jullien, Antoine Kimmoun, et al.
Annals of the Rheumatic Diseases|November 26, 2018
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trialMichelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, et al.
Circulation|April 11, 2014
High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC studyGilles Montalescot, Grégoire Rangé, Johanne Silvain, et al.
Thrombosis and Haemostasis|September 17, 2021
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT StudyIsabelle Mahé, Giancarlo Agnelli, Cihan Ay, et al.
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
Archives of Cardiovascular Diseases|June 4, 2024
Phenotypic clustering of patients hospitalized in intensive cardiac care units: Insights from the ADDICT-ICCU studyKenza Hamzi, Emmanuel Gall, François Roubille, et al.
Pageof 53

Showing results (471-480 of 522) with videos related to

Sort By:
Pageof 53
European Heart Journal. Acute Cardiovascular Care|August 26, 2017
Clinical impact and predictors of complete ST segment resolution after primary percutaneous coronary intervention: A subanalysis of the ATLANTIC TrialEnrico Fabris, Arnoud van 't Hof, Christian W Hamm, et al.
The New England Journal of Medicine|November 6, 2012
Bedside monitoring to adjust antiplatelet therapy for coronary stentingJean-Philippe Collet, Thomas Cuisset, Grégoire Rangé, et al.
Circulation. Cardiovascular Interventions|July 18, 2020
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot StudyGuillaume Duthoit, Johanne Silvain, Eloi Marijon, et al.
Circulation|September 2, 2024
Flecainide to Prevent Atrial Arrhythmia After Patent Foramen Ovale Closure: AFLOAT Study, A Randomized Clinical TrialMarie Hauguel-Moreau, Paul Guedeney, Claire Dauphin, et al.
American Journal of Respiratory and Critical Care Medicine|May 19, 2025
Iloprost for the Treatment of Severe Septic Shock with Persistent Hypoperfusion: A Double-Blind, Randomized Controlled TrialMatthieu Legrand, Edouard Jullien, Antoine Kimmoun, et al.
Annals of the Rheumatic Diseases|November 26, 2018
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trialMichelle Rosenzwajg, Roberta Lorenzon, Patrice Cacoub, et al.
Circulation|April 11, 2014
High on-treatment platelet reactivity as a risk factor for secondary prevention after coronary stent revascularization: A landmark analysis of the ARCTIC studyGilles Montalescot, Grégoire Rangé, Johanne Silvain, et al.
Thrombosis and Haemostasis|September 17, 2021
Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT StudyIsabelle Mahé, Giancarlo Agnelli, Cihan Ay, et al.
Journal of Crohn'S & Colitis|September 10, 2025
Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAIDPauline Wils, Romain Altwegg, Anthony Buisson, et al.
Archives of Cardiovascular Diseases|June 4, 2024
Phenotypic clustering of patients hospitalized in intensive cardiac care units: Insights from the ADDICT-ICCU studyKenza Hamzi, Emmanuel Gall, François Roubille, et al.
Pageof 53